Alaunos Therapeutics (TCRT) Accounts Payables (2016 - 2025)
Alaunos Therapeutics (TCRT) has disclosed Accounts Payables for 15 consecutive years, with $843000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Accounts Payables rose 84.06% year-over-year to $843000.0, compared with a TTM value of $843000.0 through Sep 2025, up 84.06%, and an annual FY2024 reading of $516000.0, down 16.23% over the prior year.
- Accounts Payables was $843000.0 for Q3 2025 at Alaunos Therapeutics, up from $285000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $4.2 million in Q1 2021 and bottomed at $262000.0 in Q1 2025.
- Average Accounts Payables over 5 years is $1.1 million, with a median of $843000.0 recorded in 2025.
- The sharpest move saw Accounts Payables skyrocketed 958.08% in 2021, then crashed 85.56% in 2022.
- Year by year, Accounts Payables stood at $1.4 million in 2021, then rose by 1.54% to $1.4 million in 2022, then crashed by 55.65% to $616000.0 in 2023, then dropped by 16.23% to $516000.0 in 2024, then surged by 63.37% to $843000.0 in 2025.
- Business Quant data shows Accounts Payables for TCRT at $843000.0 in Q3 2025, $285000.0 in Q2 2025, and $262000.0 in Q1 2025.